Stocktoria
KALA BIO, Inc. KALA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-07-20
KALA BIO, Inc. statistics & valuation
Market cap$46.8M
P / B6.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | -2099.3% | -1158.8% |
| Net margin | — | — | — | -1151.6% | -1268.7% |
| Return on assets | -284.3% | -69.4% | -75.4% | -51.6% | -102.3% |
| Return on equity | -385.6% | -312.3% | -562.4% | -236.2% | -848.6% |
| Debt / equity | — | 2.37× | 4.56× | 2.28× | 4.76× |
| Current ratio | 3.81 | 3.11 | 6.33 | 3.35 | 3.32 |
| Revenue growth | — | — | -100.0% | -65.4% | 76.7% |
Source: SEC EDGAR filings · CIK 0001479419 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.